BioSpace News Archive

NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of Clinlogix, a leading, Philadelphia-based global clinical research organization.

Scientists at Children’s Hospital of Philadelphia have identified two proteins that could be used for a potential vaccine against nontypeable Haemophilus influenzae.

The Asia Group, LLC (“TAG”), a leading Washington-based strategic advisory firm supporting global businesses and investors across the Indo-Pacific, is proud to announce its efforts as principal strategic and sales advisor to a groundbreaking collaboration and licensed production agreement between Arcturus Therapeutics Holdings Inc. (ARCT) and Vinbiocare Biotechnology Joint Stock Company,

Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, announced that the company will release financial results for the second quarter 2021 after the market close on Monday, August 9, 2021.

Oncternal Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that management will participate in the BTIG Virtual Biotechnology Conference being held August 9-10, 2021.

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, announced the appointment of a new Director and Chairperson to its Board of Directors.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended June 30, 2021.

Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, or immuno-dermatology, announced leadership additions to investor relations and communications functions.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the second quarter 2021 and reaffirmed its financial guidance for 2021.

Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, announced that management will be participating in the following virtual investor conferences.